Gaining Insight into Mitochondrial Targeting: AUTAC-Biguanide as an Anticancer Agent.
Julie VattéVéronique BourdeauGerardo FerbeyreAndreea-Ruxandra SchmitzerPublished in: Molecules (Basel, Switzerland) (2024)
AUTAC-Biguanide is a hybrid compound designed to target mitochondria, inducing their degradation by mitophagy. This study unveils the potential of biguanides as cancer cell-targeting agents, emphasizing AUTAC-Biguanide's superior antiproliferative properties compared to metformin and its selectivity for cancer cells. The mechanism behind this heightened effect includes the ability of AUTAC-Biguanide to trigger mitophagy. By providing a comprehensive analysis of these findings, this study adds valuable insights to the field of mitochondrial-targeting anticancer agents.